MPP-Unitaid report released

In November, the MPP and Unitaid jointly published a study of the patent landscape for the long-acting technologies that could have major impact for preventing or treating major diseases in low- and middle-income countries. The report provides an overview of the intellectual property status of long-acting products for major infectious diseases that are under development or already on the market.

“To avoid the pitfalls of the past, when new medicines were introduced first in high-income countries and only much later in LMICs, we need to be thinking ahead of the curve to prepare for a healthy market and prompt access to these game-changing long-acting tools”

Lelio Marmora
Executive Director, Unitaid
**Interactive ARV projections tool launched**

Since 2013, WHO and the MPP have collaborated on ARV projections incorporating technical advice, medical inputs and data from several partners as well as information about the latest scientific advancements.

In order to make these projections more accessible and user-friendly, the MPP developed an interactive ARV projections tool to assist manufacturing companies and other industry partners in the decision-making. Modelled from the joint WHO-MPP peer-reviewed projections, the tool provides active pharmaceutical ingredients and regimen-wise projections for adults and children, first- and second-line treatment segments.

**Annual Prioritisation Report**

In July, the MPP published its annual Prioritisation Report, a list of HIV, HCV and for the first time TB targeted medicines for in-licensing. If developed, these medicines could improve standard of care for people living in LMICs. This year a watchlist was created with an additional three HIV products.

The evaluation methodology, developed in collaboration with a broad range of experts, selects medicines for in-licensing based on the clinical importance of the candidate medicines; intellectual property and the extent to which medicines are patented in developing countries; existing licensing agreements in place; and potential for market uptake.

**HIV PRIORITISATION**
cabotegravir

**WATCHLIST**
doravirine
fostemsavir
rilpirvirine long-acting injectable

**HCV PRIORITISATION**
giecaprevir/pibrentasvir

**TB PRIORITISATION**
bedaquiline
delamanid
pretomanid

**MedsPaL – The Medicines Patents and Licences Database**

Launched in 2016, the Medicines Patents and Licences database (MedsPaL) is a free resource that provides information on the intellectual property status of selected HIV, HCV, TB and other patented essential medicines in LMICs. The MPP collects patent and licensing data from several sources including through collaboration agreements with national and regional patent offices, which include the African Regional Intellectual Property Organization, the European Patent Office, the World Intellectual Property Organization (WIPO) and several national patent offices around the world:

- **Argentina’s National Institute of Industrial Property** (INPI)
- **Brazil’s National Institute of Industrial Property** (INPI)
- **Chile’s National Institute of Industrial Property** (INAPI)
- **Dominican Republic’s National Office of Industrial Property** (ONAPI)
- **Ecuador Industrial Property Institute** (IEPI)
- **El Salvador’s National Registry Center** (CNR)
- **Peru’s National Institute for the Defense of Free Competition and the Protection of Intellectual Property** (INDECOPI)
- **South Africa’s Companies and Intellectual Property Commission** (CIPC)
- **Uruguay’s National Directorate of Industrial Property** (DNPI)

As of December 2018, the database covered 6,800 national patent applications on 70 priority medicines (130+ formulations) in more than 110 LMICs.

**New features of MedsPaL** were launched during the 29th Session of the Standing Committee on the Law of Patents of WIPO in December 2018. Key features include a map view, product grouping and clear search functions.

See more at medspal.org